ROS1+ Non-Small Cell Lung Cancer: Entrectinib Shows Promise

Results have been strong for phase 1 and 2 clinical trials of entrectinib (RXDX-101), an orally available selective tyrosine kinase inhibitor, in treatment of patients with ROS1-positive non-small cell lung cancer (NSCLC). A ROS1 rearrangement is a chromosomal abnormality where ROS1 has mutated so that it signals cells to continuously survive and multiply, thereby causing cancer. ROS1-positive NSCLC is a distinct molecular subset of NSCLC that occurs in 1% to 2% of lung cancer cases. Compared wi...
Continue reading


Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.